知名投资机构Shah Capital近日公开呼吁生物技术公司诺瓦瓦克斯医药采取积极资本管理措施，建议其尽快赎回市场上流通的2.25亿美元可转换债券，同时考虑启动规模达1000万至2000万股的股票回购计划。
这一举措被市场解读为股东对提升公司估值的最新努力。通过削减债务规模和回购股份，诺瓦瓦克斯医药有望优化资本结构，进一步提升每股收益指标。可转债的提前赎回将有效降低财务杠杆，而股份回购则直接向市场传递管理层对当前股价被低估的判断。
值得注意的是，诺瓦瓦克斯医药作为疫苗研发领域的重要参与者，其资本运作动向备受关注。Shah Capital的建议若被采纳，可能引发连锁市场反应。投资者正密切关注公司管理层是否会响应这一股东提案，以及后续可能采取的具体实施方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.